---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-399383"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2026-09-23T20:06:24+00:00"
generated_at: "2026-09-23T20:09:05.076324+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Zymeworks closes $17/share Theravance acquisition; issues $350M notes

## Summary
- Zymeworks completes Theravance merger; each share converted to $17.00 cash plus one CVR.
- CVR pays 80% of ampreloxetine license proceeds, $50M U.S./EU first-commercial-sale milestone, 10% net sales.
- Issued $350M senior secured notes at 8.25% fixed rate, maturing Dec 31, 2036, to OMERS-affiliated purchaser.
- Notes guaranteed by four Theravance IP subsidiaries; proceeds funded cash consideration and CVR payments.
- Investor call scheduled Sept 28, 2026, 8:30 a.m. ET to discuss closing details.

## SEC filing metadata
- accession: 0001193125-26-399383
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2026-09-23T20:06:24+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312526399383/0001193125-26-399383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312526399383/d270232d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-399383
- JSON: https://secwatch.observer/filing/0001193125-26-399383.json
- Plain text: https://secwatch.observer/filing/0001193125-26-399383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.